OTLC Stock Overview
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications.
Oncotelic Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.05|
|52 Week High||US$0.26|
|52 Week Low||US$0.045|
|1 Month Change||-14.48%|
|3 Month Change||-38.39%|
|1 Year Change||-70.48%|
|3 Year Change||-75.81%|
|5 Year Change||n/a|
|Change since IPO||-54.91%|
Recent News & Updates
|OTLC||US Biotechs||US Market|
Return vs Industry: OTLC underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: OTLC underperformed the US Market which returned -14.9% over the past year.
|OTLC Average Weekly Movement||21.8%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: OTLC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: OTLC's weekly volatility has increased from 15% to 22% over the past year.
About the Company
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company’s lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma.
Oncotelic Therapeutics, Inc. Fundamentals Summary
|OTLC fundamental statistics|
Is OTLC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OTLC income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.022|
|Net Profit Margin||0.00%|
How did OTLC perform over the long term?See historical performance and comparison